Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
GlaxoSmithKline, Vir Biotechnology announce rolling EMA review of sotrovimab » 05:58
05/07/21
05/07
05:58
05/07/21
05:58
GSK

GlaxoSmithKline

$37.93 /

+0.14 (+0.37%)

, VIR

Vir Biotechnology

$41.67 /

-1.75 (-4.03%)

GlaxoSmithKline (GSK) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
$41.67 /

-1.75 (-4.03%)

GSK GlaxoSmithKline
$37.93 /

+0.14 (+0.37%)

GSK GlaxoSmithKline
$37.93 /

+0.14 (+0.37%)

04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
VIR Vir Biotechnology
$41.67 /

-1.75 (-4.03%)

03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
03/03/21 Goldman Sachs
Vir Biotechnology price target lowered to $59 from $61 at Goldman Sachs
03/03/21 H.C. Wainwright
Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright
VIR Vir Biotechnology
$41.67 /

-1.75 (-4.03%)

GSK GlaxoSmithKline
$37.93 /

+0.14 (+0.37%)

  • 08
    Jul
GSK GlaxoSmithKline
$37.93 /

+0.14 (+0.37%)

VIR Vir Biotechnology
$41.67 /

-1.75 (-4.03%)

GSK GlaxoSmithKline
$37.93 /

+0.14 (+0.37%)

GSK GlaxoSmithKline
$37.93 /

+0.14 (+0.37%)

Wednesday
Hot Stocks
GlaxoSmithKline reports European Commission approves expanded use of Benlysta » 07:09
05/05/21
05/05
07:09
05/05/21
07:09
GSK

GlaxoSmithKline

$37.51 /

-0.17 (-0.45%)

GlaxoSmithKline announced…

GlaxoSmithKline announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis in Europe, in addition to systemic lupus erythematosus. The EU marketing authorization follows the recent approval for the similar expanded LN indication in the U.S., the company noted.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.51 /

-0.17 (-0.45%)

GSK GlaxoSmithKline
$37.51 /

-0.17 (-0.45%)

04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
GSK GlaxoSmithKline
$37.51 /

-0.17 (-0.45%)

GSK GlaxoSmithKline
$37.51 /

-0.17 (-0.45%)

GSK GlaxoSmithKline
$37.51 /

-0.17 (-0.45%)

GSK GlaxoSmithKline
$37.51 /

-0.17 (-0.45%)

Tuesday
Hot Stocks
ViiV Healthcare initiates rolling submission of NDA for cabotegravir for PrEP » 07:23
05/04/21
05/04
07:23
05/04/21
07:23
GSK

GlaxoSmithKline

/

+

, PFE

Pfizer

/

+

ViiV Healthcare, the…

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced the initiation of a rolling submission of a new drug application, or NDA, with the US Food and Drug Administration for investigational, long-acting, injectable cabotegravir for the prevention of HIV, also called pre-exposure prophylaxis, or PrEP. The rolling submission allows ViiV Healthcare to submit portions of the regulatory application to the FDA as they are completed, rather than waiting until every section of the NDA is complete to submit the entire application for review. The complete submission will be based on results from two phase IIb/III studies, HPTN 083 and HPTN 084. HPTN 083 evaluated the safety and efficacy of long-acting cabotegravir for HIV prevention in men who have sex with men and transgender women.1 HPTN 084 evaluated cabotegravir for HIV prevention in women who are at increased risk of HIV acquisition.2 The Data Safety Monitoring Board stopped the blinded, randomized portion of both studies early after cabotegravir was shown to be superior to daily emtricitabine/tenofovir disoproxil fumarate tablets, ViiV noted.

ShowHide Related Items >><<
PFE Pfizer
/

+

GSK GlaxoSmithKline
/

+

GSK GlaxoSmithKline
/

+

04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
PFE Pfizer
/

+

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
PFE Pfizer
/

+

GSK GlaxoSmithKline
/

+

PFE Pfizer
/

+

GSK GlaxoSmithKline
/

+

PFE Pfizer
/

+

GSK GlaxoSmithKline
/

+

PFE Pfizer
/

+

GSK GlaxoSmithKline
/

+

Over a week ago
Recommendations
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank » 12:10
04/30/21
04/30
12:10
04/30/21
12:10
GSK

GlaxoSmithKline

$37.45 /

-0.06 (-0.16%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis raised the firm's price target on GlaxoSmithKline to 1,200 GBp from 1,150 GBp and keeps a Sell rating on the shares.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.45 /

-0.06 (-0.16%)

GSK GlaxoSmithKline
$37.45 /

-0.06 (-0.16%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$37.45 /

-0.06 (-0.16%)

GSK GlaxoSmithKline
$37.45 /

-0.06 (-0.16%)

GSK GlaxoSmithKline
$37.45 /

-0.06 (-0.16%)

GSK GlaxoSmithKline
$37.45 /

-0.06 (-0.16%)

Earnings
GlaxoSmithKline reconfirms guidance range for 2021 » 07:10
04/28/21
04/28
07:10
04/28/21
07:10
GSK

GlaxoSmithKline

$37.71 /

-0.065 (-0.17%)

GlaxoSmithKline said:…

GlaxoSmithKline said: "We reconfirm our guidance range for 2021 for a decline of mid to high-single digit percent Adjusted EPS at CER. In 2021, as planned we will continue to increase investment in our pipeline, build on our top-line momentum for key growth drivers and largely complete readiness for separation. Assuming healthcare systems and consumer trends approach normality in the second half of the year, we continue to expect Pharmaceutical revenue to grow flat to low-single digits at CER and Consumer Healthcare revenue to grow low to mid-single digits at CER excluding brands divested/under review with above market growth. For our Vaccines business, as noted at the time of announcing full-year 2020 results, we anticipated disruption during the first half of the year, given governments' prioritisation of COVID-19 vaccination programmes and ongoing measures to contain the pandemic. This was expected to impact adult and adolescent immunisations, including Shingrix, notably in the US and this is reflected in our first-quarter 2021 Vaccines performance. We are encouraged by the rate at which COVID-19 vaccinations are being deployed in many countries, particularly the US and UK, which provides support for healthcare systems returning to normal. As a consequence we remain confident in the underlying demand for our Vaccine products, and we expect strong recovery and contribution to growth, notably from Shingrix, in the second half of the year. We continue to expect Vaccines revenue for 2021 to grow flat to low-single digits at CER." A dividend of 19p was declared for Q1 and GSK said it continues to expect 80p/share for 2021.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

Earnings
GlaxoSmithKline reports Q1 adjusted EPS 22.9p vs. 37.7p a year ago » 07:09
04/28/21
04/28
07:09
04/28/21
07:09
GSK

GlaxoSmithKline

$37.71 /

-0.065 (-0.17%)

Group turnover was EUR…

Group turnover was EUR 7.42B in the quarter, down 18% AER, 15% CER. Excluding the impact of brands divested or under review in Consumer Healthcare, Group turnover was down 13% at CER. Emma Walmsley, CEO of GSK, said: "Our first quarter results are in line with our expectations and reflect the anticipated impacts of COVID-19. We continue to expect a significant improvement in performance over the remainder of the year and reconfirm our guidance for 2021 and 2022 outlook. The launch of Cabenuva for HIV and Phase III starts for our RSV vaccine and a new long-acting treatment for severe asthma are key milestones as we continue to strengthen our growth prospects. Separation plans are also well underway and we look forward to sharing our strategy and growth outlook for New GSK with investors in June."

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

GSK GlaxoSmithKline
$37.71 /

-0.065 (-0.17%)

Options
GlaxoSmithKline call volume above normal and directionally bullish » 12:05
04/27/21
04/27
12:05
04/27/21
12:05
GSK

GlaxoSmithKline

$37.78 /

+0.005 (+0.01%)

Bullish option flow…

Bullish option flow detected in GlaxoSmithKline with 3,806 calls trading, 1.9x expected, and implied vol increasing over 7 points to 28.45%. 4/30 weekly 37.5 calls and May-21 35 puts are the most active options, with total volume in those strikes near 3,400 contracts. The Put/Call Ratio is 0.35. Earnings are expected on April 28th.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.78 /

+0.005 (+0.01%)

GSK GlaxoSmithKline
$37.78 /

+0.005 (+0.01%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$37.78 /

+0.005 (+0.01%)

GSK GlaxoSmithKline
$37.78 /

+0.005 (+0.01%)

GSK GlaxoSmithKline
$37.78 /

+0.005 (+0.01%)

GSK GlaxoSmithKline
$37.78 /

+0.005 (+0.01%)

Hot Stocks
AnaptysBio granted conditional marketing authorization for JEMPERLI » 10:36
04/23/21
04/23
10:36
04/23/21
10:36
ANAB

AnaptysBio

$23.51 /

+0.63 (+2.75%)

, GSK

GlaxoSmithKline

$37.58 /

-0.1 (-0.27%)

AnaptysBio (ANAB)…

AnaptysBio (ANAB) announced that the European Commission has granted conditional marketing authorization for JEMPERLI for use in women with mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation antibody platform and subsequently developed by TESARO, Inc., now a part of GSK (GSK), under a collaboration agreement. Eight AnaptysBio-generated therapeutic antibodies have advanced into clinical development to date, and JEMPERLI is the first AnaptysBio-generated antibody to obtain regulatory approval. JEMPERLI is indicated as a monotherapy for treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer, who have progressed on, or are being dosed following, prior treatment with a platinum-containing regimen, and is the first indication approved by the European Commission for JEMPERLI. AnaptysBio has earned a $10M milestone payment as a result of this approval.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.58 /

-0.1 (-0.27%)

ANAB AnaptysBio
$23.51 /

+0.63 (+2.75%)

ANAB AnaptysBio
$23.51 /

+0.63 (+2.75%)

03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 Truist
AnaptysBio upgraded to Buy from Hold at Truist
03/16/21 Truist
AnaptysBio upgraded to Buy from Hold at Truist
03/09/21 Wedbush
AnaptysBio downgraded to Neutral at Wedbush
GSK GlaxoSmithKline
$37.58 /

-0.1 (-0.27%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$37.58 /

-0.1 (-0.27%)

ANAB AnaptysBio
$23.51 /

+0.63 (+2.75%)

GSK GlaxoSmithKline
$37.58 /

-0.1 (-0.27%)

GSK GlaxoSmithKline
$37.58 /

-0.1 (-0.27%)

ANAB AnaptysBio
$23.51 /

+0.63 (+2.75%)

GSK GlaxoSmithKline
$37.58 /

-0.1 (-0.27%)

Hot Stocks
GlaxoSmithKline reports European Commission approves Jemperli » 10:22
04/23/21
04/23
10:22
04/23/21
10:22
GSK

GlaxoSmithKline

$37.65 /

-0.03 (-0.08%)

GlaxoSmithKline announced…

GlaxoSmithKline announced the European Commission has granted conditional marketing authorization for Jemperli, a programmed death receptor-1-blocking antibody, for use in women with mismatch repair-deficient/microsatellite instability-high recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen. "The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe," the company stated.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.65 /

-0.03 (-0.08%)

GSK GlaxoSmithKline
$37.65 /

-0.03 (-0.08%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$37.65 /

-0.03 (-0.08%)

GSK GlaxoSmithKline
$37.65 /

-0.03 (-0.08%)

GSK GlaxoSmithKline
$37.65 /

-0.03 (-0.08%)

GSK GlaxoSmithKline
$37.65 /

-0.03 (-0.08%)

Hot Stocks
Roche announces FDA approval of VENTANA MMR RxDx panel » 06:41
04/23/21
04/23
06:41
04/23/21
06:41
RHHBY

Roche

$42.52 /

-0.67 (-1.55%)

, GSK

GlaxoSmithKline

$37.67 /

-0.575 (-1.50%)

Roche (RHHBY) announced…

Roche (RHHBY) announced U.S. Food and Drug Administration approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with Jemperli monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on April 22, 2021.

ShowHide Related Items >><<
RHHBY Roche
$42.52 /

-0.67 (-1.55%)

GSK GlaxoSmithKline
$37.67 /

-0.575 (-1.50%)

RHHBY Roche
$42.52 /

-0.67 (-1.55%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
GSK GlaxoSmithKline
$37.67 /

-0.575 (-1.50%)

04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
03/23/21
Fly Intel: Top five analyst downgrades
RHHBY Roche
$42.52 /

-0.67 (-1.55%)

GSK GlaxoSmithKline
$37.67 /

-0.575 (-1.50%)

RHHBY Roche
$42.52 /

-0.67 (-1.55%)

GSK GlaxoSmithKline
$37.67 /

-0.575 (-1.50%)

RHHBY Roche
$42.52 /

-0.67 (-1.55%)

GSK GlaxoSmithKline
$37.67 /

-0.575 (-1.50%)

GSK GlaxoSmithKline
$37.67 /

-0.575 (-1.50%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.